Healthcare Equipment and Supplies
Company Overview of Infraredx, Inc.
Infraredx, Inc. operates as a cardiovascular imaging company. The company engages in advancing the diagnosis and treatment of coronary artery diseases. The company’s products include dual-modality near-infrared spectroscopy intravascular ultrasound (IVUS) true vessel characterization imaging systems for identifying lipid core coronary plaques, and providing structural plaque information with IVUS; and optical catheters that provides a high resolution image of the structure of the plaque, as well as associated accessories. It serves hospital sites in the United States and Europe. The company was founded in 1998 and is headquartered in Burlington, Massachusetts.
34 Third Avenue
Burlington, MA 01803
Founded in 1998
Key Executives for Infraredx, Inc.
Chief Executive Officer and President
Compensation as of Fiscal Year 2014.
Infraredx, Inc. Key Developments
InfraReDx Seeks Acquisitions
Dec 22 14
InfraReDx, Inc. has filed an IPO in the amount of $55 million. InfraReDx said, "We may use a portion of our net proceeds to acquire and invest in complementary products, technologies or businesses; however, we currently have no agreements or commitments to complete any such transaction and are not involved in negotiations to do so."
Infraredx Receives Regulatory Approval of TVC Imaging System in Japan
Sep 29 14
Infraredx, Inc. announced that its first-in-class, dual-modality intravascular imaging technology, TVC Imaging System(TM), and its TVC Insight(TM) Catheter received Shonin approval from the Japanese Ministry of Health, Labour and Welfare (MHLW). The TVC System makes it possible to determine the structure and chemical composition of the coronary plaques that complicate stenting, and are associated with heart attacks. The TVC Imaging System console and catheter will be exclusively distributed by Goodman, a subsidiary of Osaka-based Nipro Corporation, which has extensive experience commercializing IVUS and other imaging technologies in Japan. The TVC Imaging System integrates near-infrared spectroscopy (NIRS) to detect lipid-core plaques and enhanced intravascular ultrasound (IVUS) to visualize vessel structure, including the presence of plaques and the degree of stenosis (narrowing) due to plaque build-up. Lipid core plaque is a fatty coronary artery plaque associated with most heart attacks. The TVC Imaging System can identify plaques suspected to be vulnerable to rupture, which can cause a heart attack.
Infraredx Announces the First Patient Enrolled in the Prospect II Study on the Detection and Treatment of the Vulnerable Plaques Suspected to Cause Heart Attacks
Jun 30 14
Infraredx, Inc. announced the first patient enrolled in PROSPECT II, a multi-center, prospective study designed to assess the ability of intravascular imaging to identify non-flow obstructing vulnerable plaques. Lipid core plaque (LCP), which is suspected to be vulnerable plaque, is a type of fatty coronary artery plaque implicated in most heart attacks, and will be identified using the Infraredx TVC Imaging System(TM), a first-in-class dual modality intravascular imaging system. The study's first patient was enrolled by David Erlinge, MD, PhD, one of the study's principal investigators, from Lund University in Sweden. The TVC Imaging System is the only device approved by the FDA to detect the presence of LCPs. The technology integrates near-infrared spectroscopy (NIRS) to detect LCPs, with enhanced intravascular ultrasound (IVUS) to visualize the vessel structure, and is used to guide percutaneous coronary interventions (PCI). Infraredx will provide the primary funding for the study, with additional support from The Medicines Company and Abbott Vascular.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|